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ExtEndEd rEport
Spectrum of lymphomas across different drug 
treatment groups in rheumatoid arthritis: a European 
registries collaborative project
Louise K Mercer,1 Anne C regierer,2 xavier Mariette,3 William G dixon,1 
Eva Baecklund,4 Karin Hellgren,5 Lene dreyer,6,7 Merete Lund Hetland,8,9 
rené Cordtz,6,7 Kimme Hyrich,1,10 Anja Strangfeld,2 Angela Zink,2,11 Helena Canhao,12 
M Victoria Hernandez,13 Florence tubach,14 Jacques-Eric Gottenberg,15 
Jacques Morel,16 Jakub Zavada,17 Florenzo Iannone,18 Johan Askling,5 Joachim Listing2
AbstrACt
background Lymphomas comprise a heterogeneous 
group of malignant diseases with highly variable 
prognosis. rheumatoid arthritis (rA) is associated with 
a twofold increased risk of both Hodgkin’s lymphoma 
(HL) and non-Hodgkin’s lymphoma (nHL). It is unknown 
whether treatment with biologic disease-modifying 
antirheumatic drugs (bdMArds) affect the risk of specific 
lymphoma subtypes.
Methods patients never exposed to (bionaïve) or ever 
treated with bdMArds from 12 European biologic 
registers were followed prospectively for the occurrence 
of first ever histologically confirmed lymphoma. patients 
were considered exposed to a bdMArd after having 
received the first dose. Lymphomas were attributed to 
the most recently received bdMArd.
results Among 124 997 patients (mean age 59 years; 
73.7% female), 533 lymphomas were reported. of 
these, 9.5% were HL, 83.8% B-cell nHL and 6.8% t-cell 
nHL. no cases of hepatosplenic t-cell lymphoma were 
observed. diffuse large B-cell lymphoma (dLBCL) was the 
most frequent B-cell nHL subtype (55.8% of all B-cell 
nHLs). the subtype distributions were similar between 
bionaïve patients and those treated with tumour necrosis 
factor inhibitors (tnFi). For other bdMArds, the numbers 
of cases were too small to draw any conclusions. patients 
with rA developed more dLBCLs and less chronic 
lymphocytic leukaemia compared with the general 
population.
Conclusion this large collaborative analysis of 
European registries has successfully collated subtype 
information on 533 lymphomas. While the subtype 
distribution differs between rA and the general 
population, there was no evidence of any modification of 
the distribution of lymphoma subtypes in patients with 
rA treated with tnFi compared with bionaïve patients.
IntroduCtIon
Malignant lymphomas (‘lymphomas’) comprise a 
heterogeneous group of malignant diseases with 
presumably distinct aetiologies. Whereas the 5-year 
overall survival across all lymphomas is approx-
imately 60%, there is great variation in survival 
depending on the lymphoma subtype, ranging from 
life expectancy comparable to the general popula-
tion in nodular lymphocyte predominant Hodgkin’s 
lymphoma (HL) to 5-year survival of <40% for 
T-cell lymphomas.1 Furthermore, clinical charac-
teristics and therapy approaches vary to a great 
extent according to subtype. The age-standardised 
incidence rate (IR) in Europe of approximately 
25/100 0002 makes lymphoma one of the 10 most 
common cancer types in the general population. 
There are significant gender and age-dependent 
differences, with men having higher IRs in most 
subtypes and being diagnosed at younger ages.1
In rheumatoid arthritis (RA) the overall incidence 
of lymphoma is approximately doubled compared 
with that in the general population.3–9 The associa-
tion between RA disease activity and lymphoma risk 
is considered one reason for this increased risk.10
Evidence that chronic immune stimulation/
chronic inflammation has a pathogenic effect in 
lymphomagenesis comes from the publication by 
Baecklund et al.10 This study described an ‘excess’ 
risk strongly linked to the cumulative activity of the 
disease, especially for diffuse large B-cell lymphoma 
(DLBCL), the most common type of aggressive 
B-cell lymphomas.10 Moreover, an association of 
methotrexate (MTX) treatment with Epstein-Barr 
virus (EBV)-positive lymphoproliferative disor-
ders has been described.11 Furthermore, a possible 
association between the use of tumour necrosis 
factor inhibitors (TNFi) and a rare but prognosti-
cally unfavourable hepatosplenic subtype of T-cell 
lymphoma has been reported.12
A number of European and other rheumatology 
registers have reported on the overall risk of 
lymphoma in patients with RA treated or not with 
TNFi5 13 14 and did not find a further risk increase 
related to the treatment. However, the influence of 
TNFi is a matter of debate as recent reports from 
Asia and French data on Crohn’s disease have 
shown a higher lymphoma risk in TNFi-treated 
patients.15–17
The notion that RA disease activity may be a 
strong risk determinant suggests that the overall 
lymphoma risk in TNFi-treated RA compared with 
the general population may represent a composite 
wherein a decreased risk for a disease-related 
lymphoma subset may be replaced by an increased 
risk for a treatment-related subtype. However, 
there is no definitive evidence for any influence of 
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RA treatment on subtype distribution. In contrast to estimations 
of overall lymphoma risk in RA, which can be accomplished in 
individual registers, any analysis of subtype distribution requires 
large data sets and hence an international collaboration of RA 
registers.
The main aim of this collaborative analysis was, therefore, to 
explore whether there might be a switch in the subtype distri-
bution of lymphomas in RA linked to specific antirheumatic 
treatments; if so, the finding would support the above-men-
tioned ‘exchange of risks.’ To this end, patients with RA never 
exposed to bDMARDs (bionaïve) were compared with patients 
with RA treated with bDMARDs, mainly TNFi, with respect to 
lymphoma subtypes across several European RA registries. To 
place the RA results into context, a second rationale of the study 
was to analyse the size and direction of any shift in the spectrum 
of lymphoma subtypes in patients with RA compared with the 
general population.
PAtIents And Methods
Participating registers
Twelve European biologic registers from nine countries partic-
ipated in this collaborative project of the European League 
Against Rheumatism (EULAR) Registers and Observational Drug 
Studies (RODS) Study Group: the French biologics register ‘auto-
immunity and rituximab’ (AIR),18 the Swedish ARTIS linkage 
of the Swedish Rheumatology Quality Register (SRQ) to other 
nationwide registers,13 the Czech biologics register ATTRA,19 
the Registro Español de Acontecimientos Adversos de Terapias 
Biológicas en Enfermedades Reumáticas (BIOBADASER),20 the 
British Society for Rheumatology Biologics Register for Rheu-
matoid Arthritis (BSRBR-RA),5 the Danish Rheumatologic data-
base (DANBIO),21 the Italian biologics register (GISEA),22 the 
French biologics register ‘Orencia and RA’ (ORA),18 the German 
biologics register ‘Rheumatoid arthritis observation of biologic 
therapy’ (RABBIT),23 the French Research Axed on Tolerance of 
bIOtherapies (RATIO),24 the French Register Tocilizumab and 
RA (REGATE), and the Portuguese rheumatic diseases register 
( Reuma. pt).25 To participate, registers were required to have at 
least one lymphoma reported and consequently several other 
European biologic registers were not able to contribute.
Patients
Patients were required to have physician-diagnosed RA and to be 
prospectively followed up in one of the participating European 
RA registers. Patients with a history of lymphoma prior to regis-
tration were excluded. Patients diagnosed with a histology-con-
firmed lymphoma after study registration were included in the 
analysis. These patients were stratified according to their expo-
sure status as follows: (1) bionaïve group: patients who were 
bionaïve at the diagnosis of the lymphoma; and (2) patients who 
were not bionaïve at the diagnosis of the lymphoma were strati-
fied into four groups according to the biologic disease-modifying 
antirheumatic drug (bDMARD) they had received most recently 
prior to the development of the lymphoma: TNFi, rituximab, 
tocilizumab or abatacept.
outcome
The primary endpoint was the spectrum of lymphoma subtypes. 
The definition of lymphoma included HL and non-Hodgkin's 
lymphoma (NHL), but not plasma cell neoplasias. The subtypes 
were defined according to the pathology reports. The WHO 
2008 classification of lymphomas was used to classify the respec-
tive subtype of lymphoma.26 Crude IRs were also calculated.
Three registries received reports of histologically confirmed 
lymphoma through linkage of all participants to their national 
cancer registry: DANBIO, ARTIS and BSRBR-RA. The remaining 
registers (as well as BSRBR-RA) received reports of lymphoma 
from the patient’s rheumatologist. For BSRBR-RA, histolog-
ically confirmed lymphomas were included if reported from 
either record linkage or rheumatologist.
statistical analysis
The spectrum of lymphoma subtypes was compared between 
RA cohorts in two steps. In the first step, the portion of HL 
and NHL classified into B-cell lymphoma (B-NHL) and T-cell 
lymphoma (T-NHL) was compared by χ2 test and exact multino-
mial 95% CIs. HL, B-NHL and T-NHL with incomplete subtype 
information were included in this first step, whereas lymphomas 
not otherwise specified were excluded.
To describe the consistency of the findings, the results of anal-
yses based on registers with at least 30 lymphomas each in the 
bionaïve cohort and the biologic-treated cohort are shown sepa-
rately. In the second step, the subtype distributions of B-NHL 
were compared. In this comparison, B-NHLs with missing 
further subtype specification were excluded.
To compare the spectra of lymphomas observed within the RA 
cohorts with the spectrum of lymphoma subtypes in the general 
population, data from the HAEMACARE project were used.2 
HAEMACARE is a European cancer register-based project 
intended to improve the standardisation and availability of popu-
lation-based data on haematological malignancies in Europe. It 
covers approximately 30% of the European population. Forty-
eight cancer registers, operating in 20 countries, had incidence 
data for at least one of the predefined study years (2000–2002) 
and were hence included in the HAEMACARE analysis.2
To use these data for the comparison with the RA cohorts, 
we had to consider that the spectrum of lymphoma subtypes, 
especially the portion of HL versus NHL, depends on the 
underlying age distribution of the population being investi-
gated. In the general population, approximately 50% of HL 
cases, but only 10% of NHL cases, are diagnosed in subjects 
aged 45 or below. In the HAEMACARE cohort, the percentage 
of subjects with age ≤45 years was clearly higher (55%) than 
that in our RA cohorts (16%). Therefore, a lower proportion 
of incident HL cases are expected in our cohorts. For that 
reason, we used direct standardisation methods and calculated 
the expected numbers of HL, B-NHL and T-NHL in a general 
population in which the age group ≤45 years has the same 
proportion as in our sample. These expected numbers were 
used to calculate percentages of the corresponding subtypes 
and were compared with those observed in the RA cohorts. 
No adjustment was made when the spectra of B-cell lymphoma 
were compared.
results
Baseline characteristics of more than 120 000 patients with 
RA included in the analysis are shown in table 1. In total, 533 
lymphoma cases were identified. Since patient-years (pyrs) were 
not available in the RATIO and GISEA registries, we excluded 
the 27 lymphoma cases from RATIO and the 12 cases from 
GISEA in the calculation of the IR. A total of 494 lymphoma 
cases were reported in 584 236 pyrs in the remaining registers, 
corresponding to an overall crude IR of 85 per 100 000 pyrs 
(95% CI 77 to 92). The crude IR was similar between bionaïve 
and TNFi-treated patients with RA, whereas a lower incidence 
was reported in patients exposed to rituximab (table 1).
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spectrum of lymphoma subtypes in patients with rA
The spectrum of lymphoma subtypes was analysed in multiple 
steps, corresponding to progressively more detailed classifica-
tions (tables 2 and 3).
To compare possible influences of the treatment on the 
subtype distribution of lymphomas we compared patients with 
RA by treatment groups. There were no significant differences 
in the distribution of HL versus B-NHL versus T-NHL between 
bionaïve patients and TNFi-treated patients (table 2). Similar 
results were found in each of two biologic registers (ARTIS and 
BSRBR-RA) with more than 30 lymphomas in both the bionaïve 
and TNFi groups, as well as in the subgroup of the remaining 
registers (table 2). Results of the remaining registers are provided 
in online supplementary table S1.
B-NHL cases were further stratified by subtype (table 3). The 
most frequent subtype in patients with RA was DLBCL, followed 
by follicular lymphoma and chronic lymphocytic leukaemia 
(CLL). No significant difference in B-NHL subtypes was 
observed between bionaïve and TNFi-treated patients (table 3).
The small numbers of HL and T-NHL cases did not allow 
further subtype analysis. No case of hepatosplenic T-cell 
lymphoma was detected.
Comparison between rA and the general population
After standardisation for age, the distribution of HL versus 
B-NHL versus T-NHL observed in the RA group with 9.5% 
HL, 83.8% B-NHL and 6.8% T-NHL was similar to the values 
estimated from the general population data (10.1% HL, 82.6% 
B-NHL and 7.3% T-NHL, table 2).
Comparison within the B-NHL subtype, however, showed 
that DLBCL was significantly over-represented in subjects with 
RA compared with the general population (56% of all B-NHL 
in RA vs 30% in the general population; table 3); whereas CLL 
was significantly less frequent (16% of all B-NHL in RA vs 38% 
in the general population; table 3).
dIsCussIon
The main aim of this collaborative study was to compare the 
distribution of lymphoma subtypes between TNFi-treated and 
bionaïve patients with RA. Interestingly, we did not find any 
significant differences in these subtype distributions, neither 
when comparing the broader groups of HL versus B-NHL 
versus T-NHL nor when comparing among the B-NHL subtypes. 
This is reassuring as it does not indicate any bidirectional effect 
table 1 Baseline characteristics and crude incidence rate of lymphomas among biologic-naïve, TNFi, rituximab, tocilizumab or abatacept-treated 
patients with RA
bionaïve tnFi rituximab tocilizumab Abatacept total
No. of patients 71 088 47 864* 9094 2029 1708* 124 997*
Follow-up time (pyrs) 322 167 242 260* 29 810 2827 3352* 584 236*
Female (%) 72.1 74.8 79.0 80.1 78.0 73.7
Age mean (mean range) 61.1
(57–62)
55.0
(50–57)
57.9 (58–58) 55.9
(55–57)
57.5
(56–58)
58.5
(50–62)
No. of lymphomas 288 230 6 6 3 533
Incidence per 100 000 pyrs (95% CI) 89
(79–100)
81
(70–94)
20
(7–44)
177
(57–413)
60
(7–216)
85
(77–92)
*Because of the type of the register these data are missing from RATIO and GISEA, 38 incident TNFi-exposed lymphoma cases (RATIO: 27, GISEA: 11) and one abatacept-exposed 
patient (GISEA) were for that reason excluded from the calculation of the incidence rate.
GISEA, Italian Group for the Study of Early Arthritis; pyrs, patient-years; RA, rheumatoid arthritis; RATIO, French Research Axed on Tolerance of bIOtherapies; TNFi, tumour necrosis 
factor inhibitor.
table 2 Lymphoma subtype distribution (Hodgkin’s, B-cell and T-cell lymphomas) in patients with RA in treatment groups. ARTIS and BSRBR-RA, 
both with more than 30 lymphomas in the bionaïve and TNFi groups, are shown separately to describe the robustness of the results
n total
hodgkin’s b cell t cell nos
n % 95% CI n % 95% CI n % 95% CI n excluded
Bionaïve
  ARTIS 197 13 6.6 3.3 to 11.8 174 88.3 82.1 to 93.0 10 5.1 2.6 to 8.8 19
  BSRBR 30 5 16.7 5.1 to 37.0 22 73.3 50.9 to 88.6 3 10.0 1.8 to 29.1 4
  Other 31 3 9.7 1.8 to 28.6 24 77.4 55.3 to 91.2 4 12.9 3.2 to 32.5 7
  Total 258 21 8.1 4.7 to 12.9 220 85.3 79.3 to 90.0 17 6.6 3.6 to 11.2 30
TNFi
  ARTIS 52 6 11.5 4.0 to 26.2 40 76.9 61.1 to 88.3 6 11.5 4.0 to 26.2 7
  BSRBR 77 11 14.3 6.5 to 25.9 63 81.8 69.4 to 90.6 3 3.9 0.7 to 12.1 10
  Other 73 7 9.6 3.6 to 20.4 61 83.6 71.3 to 91.8 5 6.9 2.0 to 17.0 11
   Total 202 24 11.9 7.0 to 18.3 164 81.2 74.1 to 87.3 14 6.9 3.3 to 12.3 28
Rituximab 6 0 0 0 to 50.0 5 83.3 32.9 to 99.7 1 16.7 0.3 to 67.2 0
Tocilizumab 5 0 0 0 to 56.0 5 100 44.0 to 100 0 0 0 to 56.0 1
Abatacept 3 0 0 0 to 74.4 3 100 25.6 to 100 0 0 0 to 74.4 0
RA total 474 45 9.5 6.6 to 13.2 397 83.8 79.3 to 87.6 32 6.8 4.3 to 10.0 59
BSRBR-RA, British Society for Rheumatology Biologics Register for Rheumatoid Arthritis; NOS, not otherwise specified; RA, rheumatoid arthritis; TNFi, tumour necrosis factor 
inhibitor.
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of treatments by reducing the risk for some subtypes while 
increasing the risk of other subtypes. By contrast, the spectrum of 
lymphoma subtypes in our RA cohort showed significant differ-
ences from the spectrum described in the general population in 
Europe.2 This has been suggested in previous studies,10 27 and it 
is now confirmed by our analysis which is the largest to date. It 
is of great clinical importance as different lymphoma subtypes 
show different clinical behaviour, including wide heterogeneity 
in both prognosis and the preferred treatment approach.
The analysis of the spectrum of lymphoma subtypes is also of 
importance because there are hints that certain subtypes might 
be associated with certain therapies, for example, very rare cases 
of EBV-associated lymphoproliferative disease with MTX11 and 
hepatosplenic T-cell lymphomas with TNFi.12 Hepatosplenic 
T-cell lymphoma is a rare subtype with a very unfavourable 
prognosis and poor response to currently available treatment 
options. It occurs more often in chronically immunocompro-
mised patients. There has been a safety concern regarding its 
occurrence in patients treated with TNFi, especially in young 
male patients with Crohn’s disease.12 However, a very thor-
ough analysis of all T-cell lymphoma cases reported to the Food 
and Drug Administration between 2003 and 2010 suggested an 
increased T-cell NHL risk from TNFi use in combination with 
thiopurines but not from TNFi alone.28 We did not find any 
cases of hepatosplenic T-cell NHL in our RA patient cohorts in 
over 240 000 pyrs of follow-up in patients with RA exposed to 
TNFi, in 320 000 bionaïve pyrs or in the 36 000 pyrs in patients 
exposed to rituximab, abatacept or tocilizumab. Whether there 
were cases hidden among the group of 12 ‘T-cell NHL not 
otherwise specified,’ of which five cases were in the TNFi group, 
remains speculative.
In a recent Swedish cohort, an increased risk of HL in patients 
with RA compared with the general population and compared 
with previously reported RA cohorts has been described.6 There 
is a strong association between chronic inflammation and devel-
opment of HL.6 29 In our analysis, there was a slight numerical 
but not statistically significant increase in the proportion of HLs 
between bionaïve and TNFi-treated patients.
The development of lymphomas can occur over a prolonged 
period of time, with several months or years elapsing between 
the onset of lymphomagenesis and diagnosis. Therefore, clinical 
trials with their short follow-up times are not an appropriate 
method of studying these malignancies, whereas registers provide 
a unique opportunity to do so. In addition to the large sample 
size of 533 lymphoma cases, the largest published RA-lymphoma 
cohort to date, the strength of our study is the usage of clearly 
stated definitions for the subtypes of lymphomas. All registers 
used the same template to define subtypes based on the WHO 
2008 classification.30 Ideally, central pathological review of 
lymphoma specimens would have been preferable to standardise 
the lymphoma subtype classification; however, for feasibility 
reasons, this was not possible.
Another strength is the long follow-up time for individual 
patients, which is the prerequisite for analysing these safety 
events. Thanks to the use of unselected patients without any 
exclusion criteria we are confident that our results are represen-
tative of patients with RA from across Europe.
Despite the huge data set of more than 120 000 patients we 
were not able to analyse all different RA treatments separately 
for subtype distribution due to small numbers. For example, 
only six, six and three lymphomas occurred in patients treated 
with rituximab, tocilizumab and abatacept, respectively, at 
lymphoma diagnosis. Another limitation is the fact that the bion-
aïve patients are older than the bDMARD group (mean age 61 t
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vs 55). Since age is an important factor in lymphomagenesis, the 
comparison between the treatment groups might be affected by 
this age difference.
Due to feasibility reasons, the patients were grouped into treat-
ment groups according to the bDMARD that they have received 
most recently before the lymphoma diagnosis. A potential limita-
tion is that we cannot exclude an influence of bDMARDs used 
prior to the last one. Furthermore, we could not analyse any 
potential influence of additional therapies with MTX or other 
conventional synthetic DMARDs.
The attribution of rare events such as lymphoma in RA to the 
respective RA treatment is complex. First, there is an increased 
lymphoma risk in patients with RA compared with the general 
population.3 4 31 Second, the disease activity of RA has been iden-
tified as being of outmost importance for the development of 
lymphoma.10 However, disease activity changes over time and 
is in itself dependent on the RA treatment. In addition, disease 
activity is one of the strongest factors in the treatment decision; 
therefore, there is a considerable confounding by indication 
when analysing this context. Hence, the bionaïve patients are 
different from the bDMARD-treated patients, since bDMARDs 
are used in those patients with more severe disease. It is there-
fore reassuring that in the bDMARD group with an even higher 
a priori lymphoma risk due to higher cumulative disease activity 
the risk is not higher than in the bionaïve patients.
We were confronted with other limitations typical for collab-
orative studies on register data, namely that collating data from 
different registers does not alter the quality of data from each 
register. We therefore depended on the validity of each subco-
hort. The impact of a possible heterogeneity in the results of the 
registers was partly examined in a descriptive manner by showing 
results of the two largest registers ARTIS and BSRBR separately. 
Separate results of all registers are furthermore shown in online 
supplementary table S1.
ConClusIon
The evidence is growing that the risk of lymphoma in RA is more 
dependent on RA itself and especially the disease activity than 
on the RA treatment.5 13 Furthermore, our results are reassuring 
as the spectrum of lymphoma subtypes seems not to be altered 
by TNFi.
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